Amarin | AMRN - Koszty Sprzedaży





Koszty Sprzedaży Zmiana Data
AbbVie USD 4.22B 329M 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amarin USD 26.05M 1.41M 2025-12
AstraZeneca USD 2.52B 2.73B 2026-06
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
GlaxoSmithKline GBP 1.88B 736M 2026-03
Halozyme Therapeutics USD 108.75M 6.6M 2026-03
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 3M 5M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Novartis USD 3.71B 251M 2026-06